BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 9864914)

  • 1. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
    Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
    Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and clinical features of B-precursor childhood acute lymphoblastic leukemia showing CD2 and/or E-rosette co-expression.
    Cantù-Rajnoldi A; Putti MC; Schirò R; Biondi A; Cattoretti G; Valeggio C; Castagni M; Basso G
    Haematologica; 1992; 77(5):384-91. PubMed ID: 1362385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
    Boissel N; Auclerc MF; Lhéritier V; Perel Y; Thomas X; Leblanc T; Rousselot P; Cayuela JM; Gabert J; Fegueux N; Piguet C; Huguet-Rigal F; Berthou C; Boiron JM; Pautas C; Michel G; Fière D; Leverger G; Dombret H; Baruchel A
    J Clin Oncol; 2003 Mar; 21(5):774-80. PubMed ID: 12610173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
    Cáp J; Babusíková O; Kaiserová E; Jamárik M
    Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
    Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
    Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
    Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
    Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
    Arico M; Ziino O; Valsecchi MG; Cazzaniga G; Baronci C; Messina C; Pession A; Santoro N; Basso G; Conter V;
    Cancer; 2008 Aug; 113(3):515-21. PubMed ID: 18521927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.
    Cascavilla N; Musto P; D'Arena G; Ladogana S; Matera R; Carotenuto M
    Haematologica; 1997; 82(1):31-7. PubMed ID: 9107079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome.
    Dakka N; Bellaoui H; Bouzid N; Khattab M; Bakri Y; Benjouad A
    Pediatr Hematol Oncol; 2009 Jun; 26(4):216-31. PubMed ID: 19437324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
    Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study.
    Horibe K; Hara J; Yagi K; Tawa A; Komada Y; Oda M; Nishimura S; Ishikawa Y; Kudoh T; Ueda K
    Int J Hematol; 2000 Jul; 72(1):61-8. PubMed ID: 10979211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood.
    Wiersma SR; Ortega J; Sobel E; Weinberg KI
    N Engl J Med; 1991 Mar; 324(12):800-8. PubMed ID: 1997852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purine metabolism enzyme pattern, cytochemical characteristics and clinicopathologic features of CD10-positive childhood T-cell leukemia.
    Babusíková O; Cáp J; Hrivnáková A; Klobusická M; Mesárosová A; Koníková E
    Neoplasma; 1991; 38(6):595-602. PubMed ID: 1837333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.